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Brachial plexus lesion results in loss of motor and sensory function, being more harmful in the neonate. Therefore, this study
evaluated neuroprotection and regeneration after neonatal peripheral nerve coaptation with fibrin sealant.Thus, P2 neonatal Lewis
rats were divided into three groups: AX: sciatic nerve axotomy (SNA) without treatment; AX+FS: SNA followed by end-to-end
coaptation with fibrin sealant derived from snake venom; AX+CFS: SNA followed by end-to-end coaptation with commercial
fibrin sealant. Results were analyzed 4, 8, and 12 weeks after lesion. Astrogliosis, microglial reaction, and synapse preservation
were evaluated by immunohistochemistry. Neuronal survival, axonal regeneration, and ultrastructural changes at ventral spinal
cord were also investigated. Sensory-motor recovery was behaviorally studied. Coaptation preserved synaptic covering on lesioned
motoneurons and led to neuronal survival. Reactive gliosis andmicroglial reaction decreased in the same groups (AX+FS,AX+CFS)
at 4 weeks. Regarding axonal regeneration, coaptation allowed recovery of greater number of myelinated fibers, with improved
morphometric parameters. Preservation of inhibitory synaptic terminals was accompanied by significant improvement in themotor
as well as in the nociceptive recovery. Overall, the present data suggest that acute repair of neonatal peripheral nerves with fibrin
sealant results in neuroprotection and regeneration of motor and sensory axons.
1. Introduction
Upper and lower limb innervation is greatly affected by
brachial and lumbosacral plexus lesion, leading to loss of
motor and sensory function [1–7]. In the neonate, such
injuries are even more harmful, since surgical treatment is
limited and neuronal loss is particularly enhanced by neu-
rotrophic factors deprivation. Nonexistent or limited handl-
ing of neonatal proximal lesions results in limb dysfunction
and neuropathic pain [8–12].
Experimentally, a well-acceptedmodel tomimic axotomy
injury retrograde repercussion to spinal neurons is the neona-
tal peripheral nerve axotomy [13–18]. Sciatic nerve transec-
tion, early after birth, results in significant degeneration of
spinal motoneurons as well as sensory neurons present in the
dorsal root ganglia. Also, a number of interneurons, present
in deep spinal cord laminae, degenerate due to the loss of
input and/or output. Importantly, exogenous treatment with
neurotrophins transiently rescues a significant number of
neurons, leading to the possibility of axonal regrowth and
regeneration [19, 20].
To date, neonatal peripheral nerve repair following neu-
rotmesis is largely limited due to technical drawbacks. In fact,
to perform end-to-end coaptation by epineural/perineural
suturing in the newborn represents a major challenge. On
the contrary, reconnection of transected stumps by using bio-
compatible sealants may significantly facilitate the process,
as well as taking the advantage of employing the adhesive
as scaffold to engraft stem cells, as well as neurotrophic
substances, to the injury site.
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Fibrin sealant has been applied in neurosurgery for
decades, being effective and biocompatible, with no side
effects to the nervous system microenvironment [21]. It is
made of two main components: fibrinogen and thrombin.
Together, when activated, their interaction mimics the coag-
ulation cascade, forming a stable and adhesive clot [22].
Currently, the source of commercial fibrin sealant is the
human blood. In this regard, much effort by the Center
for the Study of Venoms and Venomous Animals (CEVAP)
has been made to produce a new fibrin sealant that uses
a serine protease from a Brazilian snake (Crotalus durissus
terrificus) with thrombin-like activity. Also, in order to avoid
human blood, bubaline-derived blood serum cryoprecipitate
has been used as the fibrinogen source. Among several advan-
tages, the nonhuman fibrin glue hampers transmission of
hepatitis and HIV/AIDS [23–27]. Also, it has a customizable
formulation that can be adjusted to increase or decrease fibrin
clot formation and stability.
Although anatomical repair of spinal roots and other
lesioned plexus components constitute the primary approach,
additional strategies are necessary to enhance neuroprotec-
tion and to improve the regenerative response of severed
neurons. This may be achieved by stem cell therapy that
has shown particularly important positive effects following
nervous system injury [28–37]. In this regard, we have already
shown evidence that mononuclear cell therapy produced
neuroprotection, preservation of synapses in the spinal cord,
and reduction of glial reaction following dorsal and ventral
horn adult lesion [38, 39].
The present work investigated the viability and efficiency
of neonatal sciatic nerve end-to-end coaptation, performed
with the application of fibrin sealant. We show that both
commercial and customized nonhuman fibrin adhesives
perform equally well and allow motor and sensory recovery
up to 12 weeks after injury.
2. Material and Methods
2.1. Fibrin Sealant. Nerve stumps coaptation was performed
by using either a commercially available fibrin sealant-
Tissucol (Baxter, Vienna, Austria) or a patented fibrin
sealant derived from snake venom, kindly supplied by
the Center for the Study of Venoms and Venomous Ani-
mals (CEVAP) of UNESP (patent registration numbers
BR1020140114327 and BR1020140114360). At the time of
use, the components were previously thawed, reconstituted,
mixed, and applied [24–27, 31].
2.2. Animals and Surgery Procedure. Two-day-old (P2) neo-
natal Lewis rats were anesthetized by hypothermia and
subjected to unilateral sciatic nerve transection at mid-thigh
level. Animals were divided into three groups: axotomy
alone (AX, 𝑛 = 30), in which a 2mm segment of the
proximal stump was resected in order to assure absence of
contact between stumps; axotomy followed by end-to-end
CEVAP’s fibrin sealant coaptation (AX+FS, 𝑛 = 30); axotomy
followed by end-to-end commercial fibrin sealant coaptation
(AX+CFS, 𝑛 = 30). An overview of the surgical procedure
is illustrated in supplementary Figure S1 (in Supplementary
Material available online at http://dx.doi.org/10.1155/2016/
9028126). All experimental conditions were assessed 4, 8,
and 12 weeks after lesion. An additional nonoperated control
group was specifically utilized for the motor test evaluation
(𝑛 = 5). Also, in order to evaluate the retrograde degeneration
of motoneurons following nerve transection without prox-
imal stump resection, an additional axotomy control group
was evaluated following stump reapposition (AX-SR; 𝑛 = 5).
Both fibrin sealants used herein are composed of three
separate solutions: (1) fibrinogen, (2) calcium chloride, and
(3) thrombin or thrombin-like (in the case of the serine
protease derived from snake venom). During surgical repair,
the first two components were applied and the proximal
and distal stumps were approximated in an end-to-end
fashion. The third sealant component was then added for
polymerization.The sciatic nerve was gently shifted to assure
the stability of the coaptation and to evaluate the success of
the repair.
The Institutional Committee for Ethics in Animal
(CEUA/UNICAMP) and The Center of Experimental and
Ethical Animal (CEEA/UNESP) approved all experiments
(proc. number 2593-1 and 904-2011, resp.), which were per-
formed in accordance with the guidelines of the NIH and the
Brazilian College for Animal Experimentation. The animals
were housed using a 12 h light/dark cycle and controlled
temperature (23∘C), with free access to food and water. Pups
were maintained with the mother until 21 days old, being
weaned afterwards.
2.3. Specimen Preparation. Animals were anaesthetized with
an overdose of Kensol (Xylasine, Ko¨ning, Argentina, 10mg/
kg) and Vetaset (Ketamine, Fort Dodge, USA, 50mg/kg),
and the vascular system was rinsed by transcardial perfusion
with phosphate buffer 0.1M (pH 7.4). For neuronal survival
counting and the immunohistochemical evaluation, subjects
(𝑛 = 5 for each group) were fixed by vascular perfusion of
10% formaldehyde in phosphate buffer (pH 7.4). The lumbar
intumescence was dissected out, postfixed overnight, washed
in phosphate buffer, and stored in sucrose 10, 20, and 30% for
24 h each, before freezing. Transverse cryostat sections (12 𝜇m
thick) of the lesioned spinal cord segments (L4, L5, and L6)
were obtained, transferred to gelatin coated slides, and stored
at −22∘C until use. For sciatic nerve regeneration analysis,
the rats were transcardially perfused with 200mL of a fixative
containing 2.5% glutaraldehyde and 1.0% paraformaldehyde
in 0.1M phosphate buffer (pH 7.4). The sciatic nerve ipsi
and contralateral to the lesion were removed and stored
overnight in the same fixative at 4∘C. The specimens were
then osmicated, dehydrated, and embedded in Durcupan
(Fluka ACS, Steinheim, Switzerland). The resin blocks were
trimmed and semithin sections (0.5 𝜇m) were obtained and
stained with 0.7% Sudan Black in 70% of ethanol solution for
morphometric analysis.
2.4. Neuronal Survival. Counting of motoneurons survival
was performed on spinal cord sections (𝑛 = 5 for each group,
ipsi and contralateral ventral horn, 4, 8, and 12 weeks after
lesion). Cryostat transverse sections were stained for 3–5min
in aqueous 1% cresyl fast violet solution at room temperature.
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The sections were then washed in distilled water, dehydrated,
and mounted with Entellan (Merck, Darmstadt, Germany).
The motoneurons were identified based on their mor-
phology and location in the ventral horn (dorsolateral lamina
IX). Only cells with visible nucleus were counted for every
twentieth section (totalizing an interval of 240𝜇m between
sections) along the lumbar enlargement, both on the ipsilat-
eral and contralateral sides of each spinal cord.
Thepercentage of surviving cells was analyzed by the ratio
of absolute numbers of motoneurons, counted per section,
on the lesioned and nonlesioned sides, respectively, and
multiplying the result by 100. Abercrombie’s formula [40] was
used to correct the duplicate counting of neurons:𝑁 = 𝑛𝑡/(𝑡+
𝑑), where𝑁 is the corrected number of neurons counted, 𝑛 is
the number of cells counted, 𝑡 is the thickness of the sections
(12 𝜇m), and 𝑑 is the average diameter of neuronal nuclei.
Since the difference in size significantly affects cell counts, the
value of 𝑑 was calculated specifically for each experimental
group (ipsilateral and contralateral). In this sense, the nuclear
diameter of 15 randomly picked neurons from each group
was measured with IMAGEJ software (version 1.33, National
Institutes of Health, USA) and themean value was calculated.
2.5. Immunohistochemistry. Slides containing transverse
spinal cord sections were incubated for 45min in a 3% BSA
solution followed by incubation with the following primary
antibodies: mouse anti-synaptophysin (Dako, Glostrup,
Denmark 1 : 200) rabbit anti-GFAP (Abcam, 1 : 1500), and
rabbit anti-Iba1 (Waco, 1 : 700). The primary antibodies were
diluted in a solution containing 1% BSA (bovine serum
albumin) and 2% triton in PB 0.1M (phosphate buffer). All
sections were incubated for three hours in a moist chamber
at room temperature. After rinsing in PB, the sections were
incubated with a Cy3-conjugated secondary antiserum
(1 : 250, Jackson Immunoresearch, West Grove, PA, USA)
for 45min in a moist chamber at room temperature. The
sections were then rinsed in PB, mounted in a mixture of
glycerol/PB (3 : 1), and observed with a Leica DM5500B
microscope coupled with a Leica DFC345 FX camera.
For quantitative measurements, three representative
images of the ipsilateral and contralateral ventral horn were
captured from each animal for all experimental groups (𝑛 = 5
for each group, ipsi and contralateral ventral horn, 4, 8, and 12
weeks after lesion). For analysis of synaptophysin immunola-
beling, the integrated density of pixels was measured in eight
areas surrounding each lateral motor nucleus motoneuron,
in the anterior horn of the spinal cord. For the analysis of
anti-glial fibrillary acidic protein (GFAP) and anti-ionized
calcium binding adaptor molecule 1 (Iba1) antibodies, the
integrated density of pixels wasmeasured in the lateral region
of the spinal cord ventral horn, as described by Oliveira et al.
and Freria et al. (2010, Supporting Information) [20, 41]. The
integrated density of pixels was calculated for each section
and then as a mean value for each spinal cord. The data are
represented as themean± standard error (SE) for each group.
2.6. Sciatic Nerve Regeneration. Morphometry, regenerated
axon area, and counting analyses were performed by sam-
pling at least 30% of each nerve cross-section (magnification
of 1,000x) using a bright field microscope (𝑛 = 5 for
each group, ipsi and contralateral ventral horn, 4, 8, and 12
weeks after lesion). Sampling bias was avoided by spreading
the micrographs systematically over the entire cross-section,
according to the procedure proposed byMayhew and Sharma
[42]. These images were used for counting the total number
of myelinated fibers. For each specimen, two fields were used
to measure the perimeter and diameter of myelinated fibers
and the myelin area, using Adobe Photoshop CS6 Extended.
These values were used to calculate the myelinated axon
diameter, fiber diameter, myelin thickness (fiber diameter,
axon diameter/2), and “𝑔” ratio (axon diameter/fiber diam-
eter) that indicate the relative success of the regeneration
process as well as myelination process. The data are shown
as mean ± SE.
2.7. Electron Microscopy. Lumbar spinal cords (𝑛 = 3 for
each group, ipsi and contralateral ventral horn, 4 weeks
after lesion) were dissected out and stored overnight in
fixative at 4∘C.The specimens were then trimmed, osmicated,
dehydrated, and embedded in Durcupan (Fluka). Ultrathin
sections from the L4–L6 segments were collected on formvar
coated copper grids, counterstained with 2% uranyl acetate
and lead citrate, and examined under a transmission electron
microscope operating at 120KV (Tecnai Biotwin G2 Spirit,
FEI Company, The Netherlands). Neurons with large cell
bodies (∼35 𝜇m in diameter), found in the sciatic motoneu-
ron pool and cut in the nuclear plane, were identified as
𝛼-motoneurons by the presence of C-type nerve terminals
and chromatolysis (axotomized side). The cell surfaces were
then sequentially digitalized at a magnification of 11,000x
with an Eagle 2K video camera (FEI Company, The Nether-
lands) connected to a computer system, and the images
mounted together using vector graphics software. Synaptic
terminals opposing the motoneuron somata were identified
and their numbers per 100𝜇m of cell membrane, as well as
the membrane covering of all the terminals (calculated in
percentage of membrane length), were determined using the
measurement tool of Image J software (version 1.33u,National
Institutes of Health (NIH), USA).
The terminals were typed as F-type (flattened synap-
tic vesicles or flattened and spherical vesicles that contain
glycine/gamma-aminobutyric acid (GABA) as neurotrans-
mitter), S-type (spherical synaptic vesicles that contain glu-
tamate as the neurotransmitter), or C-type (presence of a
subsynaptic cistern and acetylcholine as the neurotransmit-
ter), according to the procedure described by Conradi in 1969
[43] (Supplementary Figure S2). The distance between con-
secutive nerve terminals covering the motoneurons was also
determined. A total of 24 sciatic 𝛼-motoneurons from three
animals per group (two neurons per animal in four groups,
AX, AX+FS, AX+CFS, and contralateral) were quantified.
The data are represented as the mean ± SE.
2.8. Functional Analysis
2.8.1. Motor Recovery. Motor function was analyzed using
the peroneal functional index (PFI) by the walking track test
(CatWalk system, Noldus Inc., The Netherlands; 𝑛 = 5 for
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each group). In this system, the animal crosses a walkway
with an illuminated glass floor. A high speed video camera
Gevicam (GP-3360, USA) equipped with a wide-angle lens
(8.5mm, Fujicon Corp., China) is positioned underneath
the walkway and the paw prints are automatically recorded
and classified by the software. The paw prints from each
animal were obtained twice a week from the third week of
life. PFI was calculated as the distance between the third toe
and hind limb pads (print length) and the distance between
the first and fifth toes (print width). Measurements of these
parameterswere obtained from the right (unlesioned) and left
(lesioned) paw prints, and the values were calculated using
the following formula described by Bain and colleagues in
1989 [44]:
PFI = 174.9 × (EPL − NPL)
NPL
+ 80.3 ×
(ETS − NTS)
NTS
− 13.4,
(1)
where N: normal or nonoperated side; E: experimental or
operated; PL: print length; TS: total toe spread, or distance
between first to fifth toes.
2.8.2. Nociceptive Sensory Recovery. The electronic von Frey
test (Insight Instruments Inc., Ribeira˜o Preto, SP, Brazil) was
utilized to evaluate sensory function recovery (𝑛 = 5 for each
group) [45]. For that, the rats were kept inside acrylic boxes
for twenty minutes before the experiment for habituation.
Nociception threshold was measured at the plantar region
by touching the skin with a pipette tip adapted to a force
transducer, which is connected to a digital counter that shows
the force, in grams, used to trigger the paw flinch. Sensibility
intensity was evaluated twice a week, from the fourth week
after surgery. Hyperalgesia was measured by stimulating the
paw surface for six times, and the results were averaged and
shown as a mean ± SE. In order to avoid foot pad lesion
and inflammation, the maximum stimulation weight (cut-off
threshold) was set to 70 g. Each data collection was carried
out in duplicate and in a blinded manner.
2.9. Statistical Analysis. The data are presented as mean ± SE,
and the differences between groups were considered signifi-
cant when the 𝑃 value was <0.05 (∗), <0.01 (∗∗), and <0.001
(∗∗∗). Statistical analysis was performed with GraphPad
Prism 4.0 software. In this sense, data were subjected to
ANOVA followed by Bonferroni post hoc test for parametric
data or Mann-Whitney 𝑈 test for nonparametric data.
3. Results
3.1. Nerve Coaptation at Neonatal Stage Increases Long Term
Neuronal Survival. Neuronal survival was investigated as
the ipsi/contralateral ratio of motoneurons present at ven-
tral horn lamina IX. After 4, 8, and 12 weeks, a severe
degeneration motoneuron was observed in the AX group.
Coaptation groups performed equally well and presented
statistically significant rescue of axotomized motoneurons
(Figure 1, Table S1). No significant differences between the
numbers of motoneurons on the contralateral side in the dif-
ferent experimental conditions were observed. Additionally,
axotomy alone with immediate reapposition of the stumps
and followedby 2mmproximal stump resection did not differ
with regard to motoneuron survival (Supplementary Figure
S3).
3.2. Preservation of Synapses by Fibrin Sealant Coaptation.
Quantitative measurements of synaptophysin immunoreac-
tivity in the sciatic motor nuclei after axotomy (AX) and after
axotomy followed by coaptation (AX+FS; AX+CFS) were
carried out 4, 8, and 12 weeks after injury. Axotomy group
showed significant reduction of immunoreactivity ipsilateral
to the lesion side. On the contrary, synaptic covering was
preserved following coaptation in all survival times analyzed
(Figure 2, Supplementary data Table S2).
3.3. Early Postnatal Nerve Coaptation Resulted in Downreg-
ulation of Astroglial and Microglial Reaction. A significant
increase in astrocyte reactivity after axotomy was observed
four weeks after lesion (Figure 3, Supplementary data Table
S3). The coaptation with fibrin sealant decreased such
astrogliosis in all time points analyzed. Similar results were
observed in microglial reactivity, where groups with coap-
tation showed decreased microglial reaction, particularly at
four weeks after lesion (Figure 4, Supplementary data Table
S4).
4. Nerve Coaptation Allowed Myelinated
Axons Recovery
4.1. Nerve Area and Number of Regenerated Axons. Although
absence of spontaneous regeneration following axotomy
alone was observed, acute coaptation (AX+FS, AX+CFS)
resulted in axonal growth with sensorimotor recovery. Area
measurements showed no significant difference between
AX+FS andAX+CFS groups, although such nerves presented
reduced dimensions as compared to the contralateral (nonle-
sioned) samples (Table 1).
Additionally, the estimation of total number of axons
revealed no significant differences between coaptation groups
(Figure 5, Supplementary data Table S5), although signifi-
cantly reduced in comparison to the normal nerve.
4.2. Morphometric Analysis of Regenerated Nerves. Mor-
phometry revealed close to normal fiber distribution fre-
quency following fibrin sealant from CEVAP coaptation.
Of note, commercial fibrin adhesive displayed the worst
values for all parameters analyzed at four weeks after lesion,
indicating slower axonal regeneration progress (Figures 6, 7,
and 8). Such initial differencewas not present eight and twelve
weeks after lesion, so that both coaptation groups performed
in a similar fashion at later stages.
Statistical differences between groups were only observed
at four weeks after sciatic nerve coaptation. In this sense,
AX+FS displayed better recovery as compared to AX+CFS.
Such statistical evaluation is presented in detail as supple-
mentary material: Figure S4, fiber diameter; Figure S5, axon
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Figure 1: Nissl-stained spinal cord transverse sections at lamina IX illustrating the neuroprotective effect on motoneurons, 4, 8, and 12 weeks
following P2 sciatic nerve transection and repair. Note the decreased number of motoneurons ipsilateral to the lesion and the improvement
of neuronal survival in the coaptation groups. (a, b, c) Ipsilateral side, 4 weeks after lesion, groups AX, AX+FS, and AX+CFS, respectively.
(d) Contralateral side, 4 weeks after lesion. (e, f, g) Ipsilateral side, 8 weeks after lesion, groups AX, AX+FS, and AX+CFS, respectively.
(h) Contralateral side, 8 weeks after lesion. (i, j, k) Ipsilateral side, 12 weeks after lesion, groups AX, AX+FS, and AX+CFS, respectively. (l)
Contralateral side, 12 weeks after lesion. Scale bar = 50 𝜇m. (m) Ratio of neuronal survival 4, 8, and 12 weeks following P2 sciatic nerve
transection and repair. Both coaptation groups displayed a significantly increased neuronal survival in all survival times analyzed. Mean ±
SE. AX: axotomy; AX+FS: axotomy followed by coaptation with fibrin sealant derived from snake venom; AX+CFS: axotomy followed by
coaptation with commercial fibrin sealant.
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Figure 2: Immunohistochemical analysis of the spinal cord ventral horn stained with antisynaptophysin, 4, 8, and 12 weeks, following P2
sciatic nerve transection and repair. A significant preservation of synaptophysin immunoreactivity is observed in both coaptation groups in
all time analyzed. (a, b, c) Ipsilateral side, 4 weeks after lesion, groups AX, AX+FS, and AX+CFS, respectively. (d) Contralateral side, 4 weeks
after lesion. (e, f, g) Ipsilateral side, 8 weeks after lesion, groups AX, AX+FS, and AX+CFS, respectively. (h) Contralateral side, 8 weeks after
lesion. (i, j, k) Ipsilateral side, 12 weeks after lesion, groups AX, AX+FS, and AX+CFS, respectively. (l) Contralateral side, 12 weeks after lesion.
Scale bar = 50 𝜇m. (m) Synaptic covering 4, 8, and 12 weeks after injury, obtained by the ratio IL/CL (ipsi/contralateral sides) of the integrated
density of pixels at lamina IX. Observe the significant reduction of synaptic elimination in both groups repaired with fibrin sealant, in all
survival times analyzed. Mean ± SE. AX: axotomy; AX+FS: axotomy followed by coaptation with fibrin sealant derived from snake venom;
AX+CFS: axotomy followed by coaptation with commercial fibrin sealant.
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Figure 3: Immunohistochemical analysis of the spinal cord ventral horn stained with glial fibrillary acid protein (GFAP), 4, 8, and 12 weeks,
following P2 sciatic nerve transection and repair. A decrease in astrogliosis is observed in both coaptation groups, 4 weeks after lesion. (a,
b, c) Ipsilateral side, 4 weeks after lesion, groups AX, AX+FS, and AX+CFS, respectively. (d) Contralateral side, 4 weeks after lesion. (e, f,
g) Ipsilateral side, 8 weeks after lesion, groups AX, AX+FS, and AX+CFS, respectively. (h) Contralateral side, 8 weeks after lesion. (i, j, k)
Ipsilateral side, 12 weeks after lesion, groups AX, AX+FS, and AX+CFS, respectively. (l) Contralateral side, 12 weeks after lesion. Scale bar
= 50 𝜇m. (m) The mean ratio, obtained by the ratio IL/CL (ipsi/contralateral sides) of the integrated density of pixels at lamina IX. Observe
the significant reduction of astrogliosis in both groups repaired with fibrin sealant, 4 weeks after lesion. Mean ± SE. AX: axotomy; AX+FS:
axotomy followed by coaptation with fibrin sealant derived from snake venom; AX+CFS: axotomy followed by coaptation with commercial
fibrin sealant.
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Figure 4: Immunohistochemical analysis of the spinal cord ventral horn stained with ionized calcium binding adaptor protein (Iba1), 4, 8,
and 12 weeks, following P2 sciatic nerve transection and repair. A decrease in microglial reaction is observed in both coaptation groups, 4
weeks after lesion. (a, b, c) Ipsilateral side, 4 weeks after lesion, groups AX, AX+FS, and AX+CFS, respectively. (d) Contralateral side, 4 weeks
after lesion. (e, f, g) Ipsilateral side, 8 weeks after lesion, groups AX, AX+FS, and AX+CFS, respectively. (h) Contralateral side, 8 weeks after
lesion. (i, j, k) Ipsilateral side, 12 weeks after lesion, groups AX, AX+FS, and AX+CFS, respectively. (l) Contralateral side, 12 weeks after lesion.
Scale bar = 50 𝜇m. (m) The mean ratio, obtained by the ratio IL/CL (ipsi/contralateral sides) of the integrated density of pixels at lamina IX.
Observe the significant reduction of microglial reaction in both groups repaired with fibrin sealant, 4 weeks after lesion. Mean ± SE. AX:
axotomy; AX+FS: axotomy followed by coaptation with fibrin sealant derived from snake venom; AX+CFS: axotomy followed by coaptation
with commercial fibrin sealant.
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Figure 5: Representative micrographs of estimated number of regenerated myelinated axons of the sciatic nerve, 4, 8, and 12 weeks,
following P2 sciatic nerve transection and repair. Note smaller fibers and counting in both coaptation groups compared with the contralateral
nerve. Axotomy only group did not show any regenerated fiber. (a, b) Ipsilateral side, 4 weeks after lesion, groups AX+FS and AX+CFS,
respectively. (c) Contralateral side, 4weeks after lesion. (d, e) Ipsilateral side, 8 weeks after lesion, groupsAX+FS andAX+CFS, respectively. (f)
Contralateral side, 8 weeks after lesion. (g, h) Ipsilateral side, 12 weeks after lesion, groups AX+FS and AX+CFS, respectively. (i) Contralateral
side, 12 weeks after lesion. Scale bar = 10𝜇m. (j) Estimated number of regenerated myelinated fibers following P2 sciatic nerve transection
and repair. Mean ± SE. AX: axotomy; AX+FS: axotomy followed by nerve coaptation with fibrin sealant derived from snake venom; AX+CFS:
axotomy followed by coaptation with commercial fibrin sealant.
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Table 1: Regenerated sciatic nerve mean area (𝜇m2) following P2 sciatic nerve transection and repair. Mean ± SE.
Survival time (weeks after lesion) AX+FS AX+CFS Contralateral
4 65,275 ± 12.66 43,281 ± 3.07 245,655 ± 20.12
8 68,791 ± 6.93 79,175 ± 6.95 419,924 ± 54.99
12 69,526 ± 6.43 92,425 ± 13.06 420,979 ± 20.77
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Figure 6: Frequency distribution of fiber diameter of regenerated fibers, 4, 8, and 12weeks, followingP2 sciatic nerve transection and repair. (a,
b) Ipsilateral side, 4 weeks after lesion, groups AX+FS and AX+CFS, respectively. (c) Contralateral side, 4 weeks after lesion. (d, e) Ipsilateral
side, 8 weeks after lesion, groups AX+FS and AX+CFS, respectively. (f) Contralateral side, 8 weeks after lesion. (g, h) Ipsilateral side, 12
weeks after lesion, groups AX+FS and AX+CFS, respectively. (i) Contralateral side, 12 weeks after lesion. Note smaller diameter fibers in the
group AX+CFS, 4 weeks after lesion. Red boxes highlight frequency intervals with greater differences among groups. AX: axotomy; AX+FS:
axotomy followed by coaptation with fibrin sealant derived from snake venom; AX+CFS: axotomy followed by coaptation with commercial
fibrin sealant.
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Figure 7: Frequency distribution of axon diameter of regenerated fibers, 4, 8, and 12 weeks, following P2 sciatic nerve transection and repair.
(a, b) Ipsilateral side, 4weeks after lesion, groupsAX+FS andAX+CFS, respectively. (c) Contralateral side, 4weeks after lesion. (d, e) Ipsilateral
side, 8 weeks after lesion, groups AX+FS and AX+CFS, respectively. (f) Contralateral side, 8 weeks after lesion. (g, h) Ipsilateral side, 12 weeks
after lesion, groups AX+FS and AX+CFS, respectively. (i) Contralateral side, 12 weeks after lesion. Note smaller axon diameters in the group
AX+CFS, 4 weeks after lesion. Red boxes highlight frequency intervals with greater differences among groups. (AX) axotomy; (AX+FS)
axotomy followed by coaptation with fibrin sealant derived from snake venom; (AX+CFS) axotomy followed by coaptation with commercial
fibrin sealant.
diameter; and Figure S6, myelin thickness. No statistical
differences were depicted regarding the “𝑔” ratio (Figure 9),
although CFS group presented mostly under myelinated
fibers four weeks after injury.
4.3. Spinal Cord Ultrastructural Changes following Nerve
Coaptation with Fibrin Sealant. All analyzed motoneurons
showed at least one cholinergic presynaptic terminal (type C)
in apposition to the plasmatic membrane surface. Lesioned
neurons, affected by axotomy, showed changes compatible
with chromatolysis, such as displacement of the nucleus to the
periphery and decrease in cytoplasm electron density. Glial
projections were observed, in the AX group, intermingling
the space between part of the presynaptic terminals and the
postsynaptic membrane (Figure 10(a)). Fully apposed termi-
nals were depicted in the other experimental groups (Figures
10(b)–10(d)). The total synaptic covering, which represents
the motoneuron body surface in contact with presynaptic
terminals, revealed reduction of excitatory terminal covering
in all groups analyzed, when compared to the contralateral
side (Figure 10(e)).
Four weeks after lesion, nontreated neurotmesis (AX
group), presented a 41.22% covering reduction of type
S inputs when compared with contralateral side. Nerve
coaptation resulted in excitatory input preservation, with
no statistical differences between commercial and CEVAP
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Figure 8: Frequency distribution of myelin thickness of regenerated fibers, 4, 8, and 12 weeks, following P2 sciatic nerve transection and
repair. (a, b) Ipsilateral side, 4 weeks after lesion, groups AX+FS and AX+CFS, respectively. (c) Contralateral side, 4 weeks after lesion. (d, e)
Ipsilateral side, 8 weeks after lesion, groups AX+FS and AX+CFS, respectively. (f) Contralateral side, 8 weeks after lesion. (g, h) Ipsilateral
side, 12 weeks after lesion, groups AX+FS and AX+CFS, respectively. (i) Contralateral side, 12 weeks after lesion. Note decreased myelin
thickness in the group AX+CFS, 4 weeks after lesion. Red boxes highlight frequency intervals with greater differences among groups. AX:
axotomy; AX+FS: axotomy followed by coaptation with fibrin sealant derived from snake venom; AX+CFS: axotomy followed by coaptation
with commercial fibrin sealant.
sealant (Figures 10(f) and 10(g)). Fibrin sealant nerve repair
promoted even more prominent effects on inhibitory inputs
(type F boutons), showing close to normal covering (Figures
10(f) and 10(g)).
The gaps between clusters of terminals in apposition to
the postsynaptic membrane were measured. Axotomy alone
led to greater distance between terminals that contrastedwith
coaptation repair, where clusters of terminals were close to
each other (Figures 10(h)–10(k)).
4.4. Nerve Coaptation Results in Significant Partial Recovery of
the Peroneal Index as well as in the Nociception Recovery. The
recovery of motor function was studied by the walking track
test, using the CatWalk System (Noldus Inc.). Statistical anal-
ysis from peroneal functional index showed a significantly
greater peroneal functional index (PFI) following coaptation
(AX+FS, AX+CFS), regardless the nature of the fibrin sealant
(Figure 11). PFI has been chosen over sciatic functional
index (SFI), because measuring the intermediate toe spread
(ITS) was not possible. We regard that to muscle atrophy
since nerve lesion was performed in the neonatal period.
Nevertheless, PFI has successfully shown motor recovery,
indicating axonal regrowth.
The nociceptive recovery was analyzed by stimulation
of the plantar surface of the paw with electronic von Frey.
Contralateral paw showed withdraw reflex around 30 g.
Axotomy alone (AX) rats did not show withdraw behavior
at the cut-off weight, indicating lack of sensory perception
(70 g, Figure 12(a)). Both groups subjected to coaptation with
fibrin sealant (AX+FS and AX+CFS) showed lower threshold
withdrawal response (around 45 g, Figures 12(b)-12(c)).
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Figure 9: Frequency distribution of 𝑔 ratio of regenerated fibers and dot plot of g ratio/axon diameter, 4, 8, and 12 weeks, following P2 sciatic
nerve transection and repair. (a, b) Ipsilateral side, 4 weeks after lesion, groups AX+FS and AX+CFS, respectively. (c) Contralateral side, 4
weeks after lesion. (d, e) Ipsilateral side, 8 weeks after lesion, groups AX+FS and AX+CFS, respectively. (f) Contralateral side, 8 weeks after
lesion. (g, h) Ipsilateral side, 12 weeks after lesion, groups AX+FS and AX+CFS, respectively. (i) Contralateral side, 12 weeks after lesion.
Observe the shift toward the presence of greater axons with close to normal myelin thickness in both coaptation groups in all survival times
analyzed. (AX) axotomy; AX+FS: axotomy followed by coaptation with fibrin sealant derived from snake venom; AX+CFS: axotomy followed
by coaptation with commercial fibrin sealant.
5. Discussion
It is well known that neonatal axotomy results in devastating
neuronal loss in the spinal cord and dorsal root ganglia
(DRG). This is particularly because of the interruption of
neurotrophic factors production and retrograde flow, mostly
at the target organs. In fact, administration of neurotrophic
factors, such as brain derived neurotrophic factor (BDNF)
and ciliary neurotrophic factor (CNTF) rescue motoneurons
from degeneration [46]. Also, the use of cannabidiol (CBD),
a cannabinoid with neuroprotective properties, is also able to
avoid both motoneuron and DRG neurons death, following
neonatal peripheral nerve lesion [47]. In this way, early
neonatal nerve axotomy has been broadly accepted as a
consistent model for studying neuroprotection [46, 48].
Nevertheless, due to the reduced size of pups, combined
with the thin and delicate structure of the peripheral nerves
at perinatal stage, repair following transection is hardly
accomplishable.
The present work shows that end-to-end nerve coaptation
can be performed in a reproducible fashion by using fibrin
sealant as a connecting structure between proximal and distal
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Figure 10: Representative ultrastructure micrographs showing synapses opposed to 𝛼-motoneurons, following P2 sciatic nerve transection
and repair. (a) Terminal intermingled with an astrocyte projection (∗glial cell), following axotomy without repair. (b, c) Observe a close
to normal synaptic apposition in neurorrhaphy groups, AX+FS and AX+CFS, respectively. (d) Contralateral side. Scale bar = 500 nm. (e)
Quantitative ultrastructural analysis of synaptic covering. (f) Detailed quantitative analysis of F, S, and C terminals. (g) Synaptic covering
with normalized number of boutons per 100 𝜇m of motoneuron membrane. Observe a reduction in synaptic covering following axotomy
alone, 4 weeks after lesion. (h, i, j, k) Distribution of gap length between clusters of terminals apposing to motoneuron membrane in all
groups analyzed. Observe that normal neurons (k) present presynaptic terminals close to each other, not exceeding 1.4 𝜇m gap. Nerve lesion
without repair results in longer gaps between terminals (h) and nerve coaptation reduced such distances (i, j; red rectangles). AX: axotomy;
AX+FS: axotomy followed by neurorrhaphy with fibrin sealant derived from snake venom; AX+CFS: axotomy followed by neurorrhaphy with
commercial fibrin sealant. Mean ± SE.
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Figure 11: Motor function recovery up to 12 weeks after lesion by
the analysis of the peroneal nerve functional index. Observe the
significantly better performance of coaptation groups (AX+FS and
AX+CFS)when comparedwith axotomywithout repair group (AX).
AX: axotomy; AX+FS: axotomy followed by coaptation with fibrin
sealant derived from snake venom; AX+CFS: axotomy followed
by coaptation with commercial fibrin sealant; control: unlesioned
group.
stump. It is important to highlight that in humans nerve size
is larger, allowing direct suturing. In this scenario, the use
of fibrin glue may enhance repair stability and function as a
scaffold for cell migration.
In the present study, we compared two different fib-
rin adhesives, one commercial brand and another recently
developed by CEVAP. The latest is based on nonhuman
components, avoiding transmission of infectious blood-
borne diseases. The results have shown that both sealants
(commercial and CEVAP) are excellent for the coaptation
process, although CEVAP’s fibrin sealant has proven to be
easier to handle at themoment of surgery. Surgeries involving
neonatal subjects ought to be particularly fast, and clotting
speed is a crucial parameter. Due to the fact that CEVAP
derived adhesive uses bubaline fibrinogen, the concentration
of such protein in the cryoprecipitate is specially higher than
the human counterpart [49]. In turn, coagulation threshold
is significantly accelerated as well as the scaffold stability.
This in turn possibly allowed early regrowth of regenerating
axons, originated from the proximal stump, resulting in
improved morphometric parameters, four weeks after repair.
In line with the positive results described in the present
work, the fibrin sealant from CEVAP has been tested in
humans, for autologous skin grafting of the nasogenian sulcus
showing promising results. Moreover, it has been tested for
the immobilization of free periodontal gingival grafts in lower
premolars and for the treatment of chronic venous ulcers [50–
54]. Besides, recent studies also show the efficacy of this new
sealant on peripheral nerve regeneration [55, 56], treatment
of skull defects [57], and following ventral root avulsion
[58].
Neuronal death is irreparable and results in sensibility
and motor loss. It has been shown that this scenario can
be partially reversed by local or systemic administration
of trophic substances, such as neurotrophins, antioxidants,
cannabinoids, and gangliosides [47, 59, 60]. Nevertheless, the
regrowth of axons from the spinal motoneurons and DRG
neurons towards the periphery is dependent on anatomical
restauration of PNS structures. We show that coaptation at
the neonatal stage is neuroprotective by itself and generates
a permissive scaffold through which regeneration can be
successfully accomplished.The results shown herein indicate
significant preservation of motoneurons in the spinal cord,
assessed by direct counting at 4, 8, and 12 weeks after
lesion, reinforcing the long lasting positive effects of the
repair procedure. Sensory and motor recovery is also present
and could be evaluated by behavioral analysis. Nevertheless,
since nerve repair was carried out at P2, motor and sensory
evaluation could only be initiated from the third (CatWalk)
or fourth (von Frey) week of age due to animal size and
sensory-motor coordination. In turn, our data reflect already
established recovery that happened before behavior tests
could be started, what explains the rather constant peroneal
and von Frey results.
Importantly, restauration of neonatal lesion, which mim-
ics obstetric brachial plexus injury, led to preservation of
synapses, as seen by synaptophysin immunostaining. Reduc-
tion of astrogliosis and microglial reaction also contribute
to synapse stability and functionality, correlating with sub-
stantial motor and sensory recovery in AX+FS and AX+CFS
groups up to twelve weeks after surgery. In this regard,
improved peroneal index following coaptation was observed
with either fibrin sealant treatment, when compared with
axotomy alone. Such improvement indicates reestablishment
of muscle innervation as well as suprasegmental control
[61, 62]. Nociception reestablishment showed a similar time
course, suggesting sensory axon regeneration [63].
After an injury, retraction of presynaptic boutons that
appose spinal motoneurons takes place during the first week
after lesion.This event reduces synaptic transmission [64–69]
and allows the axotomized neurons to focus metabolism on
survival and regrowth of a new axon and dendrites. Herein,
synaptic covering was significantly preserved in coaptation
groups, in line with the immunohistochemical observations
(synaptophysin). A quantitative analysis of the synaptic cov-
ering for each type of presynaptic terminal showed significant
preservation of S and F type of synapses. However, the
proportion of preserved inhibitory synapses was greater than
excitatory. Such scenario, according to Linda˚ et al. [70],
facilitates neuroprotection by reducing glutamatergic exci-
totoxicity [70, 71]. Besides the prevention of excitotoxicity,
the number of preserved presynaptic terminals/100𝜇m in
apposition to the alpha-motoneuron membrane was also
increased in both coaptation groups.
Synapse dynamics also depend on astrocytes and
microglia that act in favor of maintenance of homeostasis
that is necessary to transmission and synaptic plasticity.
One well-known retrograde effect of peripheral axotomy
is the development of central astrogliosis and microglial
reaction, directly interfering on synapse stability [72–75].
GFAP and Iba1 are highly expressed proteins in astrocytes
and microglia, respectively, and are upregulated after
lesion [73, 76]. The fact that coaptation downregulates
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Figure 12: von Frey measurements (𝑛 = 5 per group, mean ± SE), 12 weeks after lesion, obtained from the right hind (CL, contralateral side,
no lesion) and left hind paw (IL, ipsilateral-lesioned side). The values are expressed in grams (g) applied to trigger the “flinch” response. (a)
Observe the complete absence of nociceptive response in the axotomy without repair group (AX). (b, c) Note significant nociceptive recovery
of both coaptation groups (AX+FS and AX+CFS, resp.). AX: axotomy; AX+FS: axotomy followed by coaptation with fibrin sealant derived
from snake venom; AX+CFS: axotomy followed by coaptation with commercial fibrin sealant.
glial reaction at lumbar spinal cord level is in line with
the positive anatomical and behavioral findings previously
discussed.
Overall, the present data suggest that acute repair of
neonatal peripheral nerve with both fibrin sealant analyzed,
namely, a commercial brand and a nonhuman derived adhe-
sive produced by CEVAP/Brazil, promotes neuroprotection
and regeneration of motor and sensory axons. Also, the
present study demonstrates that neonatal end-to-end nerve
coaptation is feasible and may in turn be of use for repairing
obstetric brachial plexus injuries.
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